ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0573

Presence of Mediterranean Fever Gene Variants Provides Protection from the Development of Lupus Nephritis in Patients with Systemic Lupus Erythematosus

Yushiro Endo1, Tomohiro Koga1 and Atsushi Kawakami2, 1Department of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Nagasaki University, Nagasaki, Japan, 2Nagasaki University, Nagasaki, Japan

Meeting: ACR Convergence 2023

Keywords: FMF, Systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 12, 2023

Title: (0543–0581) SLE – Diagnosis, Manifestations, & Outcomes Poster I

Session Type: Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Previous studies showed that the prevalence of variants in Mediterranean Fever (MEFV) genes was lower in adult patients with SLE compared to healthy population and thatlow prevalence of coexistence of FMF and SLE was observed in several large FMF cohorts, suggesting that a potential protective effect of the presence of MEFV variants and/or FMF from SLE. Also, existence of MEFV variants have been suggested to modify clinical phenotypes of SLE. In particular, the presence of the E148Q variant in the exon 2 of MEFV gene may be protective for the development of lupus nephritis among adult patients with SLE. However, all these reports showing a relationship between SLE and MEFV gene are limited to those in the Mediterranean region, where MEFV exon 10 variants are relatively common.

Methods: We conducted a retrospective analysis of 55 Japanese SLE patients between January 2008 and April 2020 at Nagasaki University Hospital. We examined whether they have MEFV variants by next-generation sequencing in the whole region of MEFV. and compared clinical characteristics of the patients based on the presence or absence of MEFV variants. We introduced a partial segment of human exon 2 of the MEFV gene with or without E148Q variant, which is common variant in MEFV gene, into MRL/lpr mice and compared those phenotypes between MRL/lpr mice expressing the wild-type MEFV gene (MRL/lprhMEFV WT) and those expressing the E148Q variant (MRL/lprhMEFV E148Q).

Results: A total of 33 out of 55 patients with SLE had one or more variants in exon 1–5 of MEFV, whereas none of the patients had a mutation in exon 10. Patients with MEFV variants exhibited significant lower presence of lupus nephritis than those without MEFV variants (P=0.007). We counted the total number of MEFV variants exhibited in each patient. The total number of MEFV variants in patients with lupus nephritis was significantly lower than those without lupus nephritis (P=0.006). Among the factors analyzed including age at onset, male gender, low CH50, anti-dsDNA Ab positive, and the total count number of MEFV variants, only the total count of MEFV gene variants were significantly associated with the presence of lupus nephritis (odds ratio [OR] 0.359, p< 0.05). Consistent with the data from patients with SLE, MRL/lprhMEFV E148Q showed the tendency of less severality in lupus nephritis (not statistically significant) and showed significantly less autoantibody production (p< 0.05). These observed differences in disease phenotypes were suggested to be attributed by reduced induction of dendritic cells (p< 0.05) followed by a decrease in memory B cells (p< 0.05).

Conclusion: Presence of MEFV variant can modify clinical type of SLE and be a protective factor against the development of lupus nephritis.

Supporting image 1


Disclosures: Y. Endo: None; T. Koga: None; A. Kawakami: None.

To cite this abstract in AMA style:

Endo Y, Koga T, Kawakami A. Presence of Mediterranean Fever Gene Variants Provides Protection from the Development of Lupus Nephritis in Patients with Systemic Lupus Erythematosus [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/presence-of-mediterranean-fever-gene-variants-provides-protection-from-the-development-of-lupus-nephritis-in-patients-with-systemic-lupus-erythematosus/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/presence-of-mediterranean-fever-gene-variants-provides-protection-from-the-development-of-lupus-nephritis-in-patients-with-systemic-lupus-erythematosus/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology